The FDA approves Mumbai, India-based Cipla Limited's generic version of Biogen's (NASDAQ:BIIB) top-selling multiple sclerosis med Tecfidera (dimethyl fumarate).
Last month, Mylan launched its version.
Tecfidera accounted for 32% of Biogen's Q2 sales.
https://seekingalpha.com/news/3617621-fda-oks-ciplas-generic-version-of-biogens-tecfidera
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.